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A B S T R A C T
Background and Purpose: The relationship between peri-operative blood transfusions (PBTs) and poor
prognosis in gastric cancer (GC) patients is still debated. The aimof this study is to examine the real prognostic
impact of PBTs in comparison to well-known prognostic factors.
Methods: We retrospectively analyzed a series of 224 patients who underwent surgery with curative intent
for GC from January 1995 to December 2011. Among 224 patients, 46 (20%) required PBTs.
Results: The overall 5-year survival was 77% in non-transfused patients and 65% in patients who received
PBTs (p =0.03). PBTs did not further stratify any recognized prognostic category (such as pT or pN according
to the 7th edition of the TNM staging system). Multivariate analysis including all known prognostic variables
(both cancer- and non-cancer-related) did not select PBTs as an independent prognostic factor. Only pre-
operative hemoglobin and albumin level, pT and operative time were signiﬁcantly associated with the
requirement for PBTs.
Conclusions: The study showed aworse prognosis for transfused patients, but PBTs seem a confounding factor
more than a prognostic indicator, as they are obviously affected by other variables.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Radical surgery with extended lymphadenectomy is the key point in
gastric cancer (GC) treatment, 1 and this often induces a signiﬁcant
intra-operative blood loss and a related need for peri-operative blood
transfusions (PBTs). Several authors in the last decade have analyzed
the possible role of PBTs in the prognosis of GC patients. However
the controversies on the relationship between blood transfusions
and poor prognosis are still far from being resolved: although many
studies do not support it, some authors state that it does exist. 2–16
The present study considers a consecutive series of patients who
underwent curative gastrectomy for GC in order to analyze the real
prognostic impact of PBTs in comparisonwithwell-known prognostic
factors.
2. Patients and methods
Clinical data have been collected from case sheets. Between January
1995 and December 2011, 224 patients with non-metastatic GC
underwent surgery with curative intent. Seventy-seven (34.4%) were
females, and 147 (65.6%) were males; the mean age was 67.0±11.6
years. The mean intra-operative blood loss was 509±407ml. All
transfused patients received packed red blood cells, and peri-
operative blood transfusions were deﬁned as the administration
of packed red blood cells within two weeks before and one
month after surgery. PBTs were administered according to clin-
ical criteria and on the basis of laboratory data: if cardiologic
comorbidities were identiﬁed, patients with a hemoglobin level
lower than 10 g/dl were pre-operatively transfused. A hemoglobin
level lower than 8.5 g/dl represented itself an indication for PBTs,
both pre- and post-operatively. In the analysis we considered
the following factors: patient’s age and gender; tumor location
(1/3 proximal versus 2/3 distal); type of surgery (total versus
subtotal gastrectomy), multivisceral resection, number of removed
nodes, peri-operative blood transfusions; hemoglobin and albumin
levels at admission, operative time, residual tumor (R), tumor
diameter, Lauren’s classiﬁcation, grading of differentiation (G), and
pT and pN classiﬁed according to the seventh TNM edition. 17 We
retrospectively considered cancer-related death as the end-point to
evaluate survival rates.
2.1. Statistical analysis
All variables were expressed as mean ± standard deviation (SS)
or median and range. Where appropriate, continuous variables
were categorized around their median value or a recognized cutoff.
Survival was calculated from the day of surgery to January 2012.
Patients who died from a non-cancer-related cause were censored
1743-9191$ – see front matter © 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
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Table 1
Clinical and pathological features. Overall survival rates and univariate analysis of the sample
Variable Number Percentage 5-year survival
(%)
p-value
Peri-operative blood transfusions 0.026
Yes 46 20.6 64.7
No 178 79.4 77.0
Age 0.518
67 108 48.2 75.9
>67 116 51.8 73.3
Gender 0.544
M 147 65.6 74.3
F 77 34.4 76.1
Tumor location 0.961
1/3 proximal 47 21.1 74.6
2/3 distal 176 78.9 74.8
Albumin level at admission (g/dl) 0.037
>3.5 168 75.0 80.5
3.5 56 25 63.0
Hemoglobin level at admission (g/dl) 0.113
12 113 50.4 81.3
<12 111 49.6 73.4
R <0.001
0 205 91.5 79.0
1–2 19 8.5 38.7
Type of gastrectomy 0.614
Total 104 46.4 74.5
Subtotal 120 53.6 75.2
Multivisceral resection 0.647
Yes 11 4.9 80.0
No 213 95.1 75.3
Number of lymph nodes removed 0.122
<16 92 41.1 72.0
16 132 58.9 58.9
Operative time (min) 0.219
180 104 46.4 80.0
>180 120 53.6 74.7
Tumor diameter (mm) 0.01
40 138 61.6 83.4
>40 86 38.4 63.1
Lauren’s classiﬁcation 0.081
Diffuse 122 54.5 69.3
Intestinal 102 45.5 81.8
Grading 0.026
1 10 4.5 100
2 95 42.4 82.1
3 119 53.1 69.3
pT <0.001
1–2 92 41.1 87.0
3–4 132 58.9 53.9
pN <0.001
0 99 44.2 94.8
+ 125 55.8 46.7
at the time of death. Survival rates were calculated by the Kaplan–
Meier method and log-rank test was used for univariate analysis.
The Cox proportional hazard model was used for multivariate
analysis, including only variables with p < 0.1 at log-rank test, with
a backward elimination model for all covariates. Hazard ratio (HR)
and 95% conﬁdence interval (CI) were calculated in the model for
each variable included. The regression model was controlled with
goodness of ﬁt tests; p < 0.05 was considered statistically signiﬁcant.
The differences among groups (PBTs versus other factors) were
evaluated by non-parametric tests. All statistical analyses were
performed using the Statistical Package for Social Sciences (SPSS)
version 13.0 for Windows©.
3. Results
The clinical and pathological sample characteristics, survival rates
and the results of the univariate analysis are reported in Table 1.
After a median follow up of 48 months, 50 patients (22.3%) had
died from GC recurrence. Subtotal gastrectomy was performed in
120 cases (53.6%), and total gastrectomy in 104 (46.4%). Multivisceral
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resection was required in 11 patients (4.9%) for suspected T4 tumors.
Two hundred and thirteen patients (95.1%) underwent a limited
lymphadenectomy (D1); a more extended lymphadenectomy (D2)
was performed in 11 cases (4.9%). Overall survival at 12, 24, 36, 48 and
60 months was, respectively, 96.2%, 87.2%, 80.0%, 74.9% and 74.1%.
Patients without PBTs showed better 5-year survival rate than
patientswith PBTs (77.0% versus 64.7%, respectively, p = 0.026; Fig. 1).
Fig. 1. Survival in transfused and in non-transfused patients.
Cox regression selected lymph node status as the only independent
prognostic factor in our series (p < 0.001).
After univariate survival analysis, we revised survival of each pT
and pN category according to need for PBTs without any relevant
statistical signiﬁcance (Table 2).
Table 2
5-year survival rates according to pT andpN stratiﬁed byneed for PBT(s)
5-year survival (%) p-value
pT
T1 Transfused 94.9% 0.682
Non transfused 100%
T2 Transfused 94.7% 0.655
Non transfused 100%
T3 Transfused 71.2% 0.645
Non transfused 70.0%
T4 Transfused 60% 0.069
Non transfused 50%
pN
N0 Transfused 94.8% 0.363
Non transfused 100%
N1 Transfused 75.7% 0.340
Non transfused 66.7%
N2 Transfused 80.0% 0.178
Non transfused 62.5%
N3 Transfused 34.8% 0.207
Non transfused 40.0%
Hemoglobin level at hospital admission (<12.0g/dl versus12.0g/dl,
p < 0.001), albumin level at admission (3.5 g/dl versus >3.5 g/dl,
p = 0.001), pT (T1–2 versus T3–4, p = 0.004), and operative time
(180min versus >180min, p = 0.031) were the only factors signiﬁ-
cantly associated with the need for PBTs.
4. Discussion
Detrimental effects of peri-operative blood transfusions on prognosis
have been observed in cancer surgery for several solid tumors. 15,18–27
However, controversies do exist, as some regard the PBT-related
deleterious effect as coincidental rather than causative. 28 The
coincidental factors resulting in more blood loss and more trans-
fusions might be related to tumor (size, depth of invasion, node
involvement), patient (age, nutritional status, and comorbidity), or
surgery (operative accident or difﬁcult dissection). 13
To date there is no suitable alternative for peri-operative blood loss
replacement than blood itself. Although the exact mechanism is not
known, it seems that PBTs increase the risk of disease recurrence
in cancer patients. Heiss et al. 29 suggested that transfusions induce
the development of a large number of residual tumor cells in the
bone marrow, leading to worse survival. Maeta et al. 7 found a
signiﬁcantly lower survival in transfused patients, but they suggested
that immunosuppression could have been due to surgical stress
rather than to PBTs. Another possible mechanism to explain this
association is the increase in morbidity related to post-operative
septic complications in transfused patients. 30,31 This could be a
consequence of immunomodulation induced by PBTs or could be
related to the circumstances requiring PBTs, as is seen in gastric
carcinoma. 32 The immunological mechanism is supported by some
studies which report a better survival in transfused patients who
underwent splenectomy, 8,33 although other authors reported differ-
ent results, with non-signiﬁcant difference in survival and a higher
recurrence rate in patients who underwent gastric resection and
splenectomy. 34
All considered studies reported that PBTs are signiﬁcant in
univariate survival analysis, but when testing it as an independent
prognostic factor in multivariate analysis, different authors found
different results. Moriguchi et al., 4 in a large series, reported PBTs not
to be an independent prognostic variable in gastric cancer patients,
while Dhar et al. 13 found blood transfusion to be an independent
prognostic factor associated with an adverse effect on the disease
recurrence. Other studies 2,3,5 reported poorer prognosis in transfused
patients, but they postulated this could be related to the more
advanced stage of disease observed in transfused patients. A higher
rate of peritoneal recurrence has been observed by Kamei et al. 10
in patients who required PBTs because of great intra-operative blood
loss, conﬁrming the importance of a clean and dry surgery.
In our study, we aimed to verify the role of PBTs in the
prognosis of gastric cancer patients who underwent radical surgery,
analyzing also variables not directly related to cancer. Actually, while
univariate analysis conﬁrmed the prognostic role of peri-operative
administration of blood (p =0.026) (Table 1, Fig. 1), multivariate
analysis did not conﬁrm that it is an independent prognostic factor.
In fact, it was not able to further signiﬁcantly stratify survivals of the
pT and pN groups (Table 2).
Furthermore, we found that the need for PBTs was signiﬁcantly
associatedwith a single factor directly related to cancer (pT, p = 0.004)
and with three non-cancer-related variables, that is, pre-operative (at
admission) albumin and hemoglobin levels (p < 0.001 and p=0.001,
respectively) and operative time (p =0.031).
Taking into consideration these results, we conclude that the need
for PBTs is strongly related to the stage of the disease and also depends
on other factors not strictly related to the disease. Hence, in gastric
cancer according to our results (although limited by the retrospective
design of the study) PBTs seem to be more a confounding factor than
a prognostic factor.
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5. Conclusion
Our analysis has not shown that peri-operative blood transfusion is
an independent prognostic factor. Moreover, it seems to be related
to several factors, directly and indirectly linked to the tumor stage,
supporting the hypothesis that PBTs is a confounding rather than
a prognostic factor in gastric cancer patients. Anyway, since at this
stage there is no clear evidence on the immunological response to
transfusion, we suggest to carefully administer PBTs minimizing at
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